What we achieved
HPP established a multi-stakeholder steering committee comprising patient advocates and experts in oncology and nuclear medicine from across Europe, to develop a policy report to raise awareness of radioligand therapy as an innovative component of cancer care. Through desk research and interviews with additional stakeholders, the report was drafted to reflect the consensus of the steering committee.
Alongside the main report, HPP created an animated video on radioligand therapy, to explain this complex process to a wider audience. We also created a two-page report summary featuring a top-line explanation of radioligand therapy and a distillation of the report’s recommended actions to overcome barriers to integration of radioligand therapy in clinical cancer care.
The report and other outputs were launched during an event at the European Parliament in Brussels on Wednesday 22 January 2020, which was co-hosted by Tanja Fajon MEP and Ewa Kopacz MEP. This was the first European-level policy meeting on radioligand therapy.
We created a dedicated website to house this project – www.radioligandtherapy.com – along with an independent Twitter account: @radioligand. A new phase of research is already underway for future work on radioligand therapy.
Key partners and stakeholders
- Dr Josep Maria Borras, Director, Catalonia Cancer Strategy, Spain
- Dr Jaroslaw Cwikla, Professor, Department of Radiology, University of Warmia and Mazury in Olsztyn, Poland
- Professor Ken Herrmann, Director, Clinic for Nuclear Medicine, University Hospital Essen, Germany
- Nikie Jervis, Specialist Nurse: Patient Support, Information & Education, NET Patient Foundation, UK
- Dr Annibale Versari, Director, Oncology and Advanced Technologies, ASMN Reggio Emilia, Italy
- Dr Harald Lahner, Deputy Director, ENETS Center of Excellence, University Hospital Essen, Germany
- Dr Jamshed Bomanji, Head of Clinical Department, Institute of Nuclear Medicine, University College London Hospital, UK
- Dr John Buscombe, President, British Nuclear Medicine Society, UK
- Dr Valentina Ambrosini, Associate Professor of Nuclear Medicine, University of Bologna, Italy